• Viperin Disrupts Coronavirus RTC via nsp8 Interaction and dd

  2026-07-01

  This study reveals that viperin restricts coronavirus replication by directly targeting non-structural protein 8 (nsp8), disrupting the assembly of the replication-transcription complex (RTC). The work highlights both ddhCTP-dependent and independent antiviral mechanisms and identifies conserved protein interaction domains, providing new targets for broad-spectrum antiviral strategies.

• Acetoacetic Acid Sodium Salt in Energy Metabolism Research

  2026-07-01

  Acetoacetic acid sodium salt is a benchmark metabolite for probing fatty acid catabolism and diabetic metabolic imbalance, offering unmatched purity and reproducibility. This guide details optimized workflows, key innovations, and troubleshooting strategies to advance translational energy metabolism and diabetes research.

• Dabigatran Etexilate: Oral Thrombin Inhibition in VTE and AF

  2026-06-30

  The reference study establishes dabigatran etexilate as the first oral, reversible direct thrombin inhibitor, offering predictable anticoagulation without routine monitoring. This innovation addresses major limitations of traditional therapies in venous thromboembolism (VTE) prevention and atrial fibrillation-related stroke, with significant implications for both clinical research and future protocol optimization.

• Dabigatran Etexilate: Reducing Drug Interactions in Anticoag

  2026-06-30

  The reference study details the clinical and pharmacokinetic advantages of dabigatran etexilate, the first oral direct thrombin inhibitor approved for stroke and VTE prevention. By being metabolized independent of the CYP450 system, dabigatran etexilate minimizes drug-drug interactions and monitoring requirements, marking a significant advance over traditional anticoagulants.

• JNJ-10198409: Precision Platelet-Derived Growth Factor Recep

  2026-06-29

  JNJ-10198409 provides nanomolar-precision PDGF-BB receptor inhibition for reproducible antiangiogenic and antiproliferative research. This guide details experimental workflows, key protocol parameters, and troubleshooting strategies that maximize data reliability in cancer biology and fibrotic disorder studies.

• WM-8014: Precision KAT6A Inhibition for Cancer Biology Resea

  2026-06-29

  WM-8014 enables highly selective, reversible inhibition of KAT6A/B, unlocking targeted oncogene-induced senescence without broad cytotoxicity. This article translates bench insights and protocol enhancements into actionable guidance for researchers leveraging WM-8014 in epigenetic and cancer biology applications.

• CF10 and EdU Synergy Drives Telomere Attrition in CRC Cells

  2026-06-28

  The 2026 study by Das et al. demonstrates that combining CF10, a second-generation fluoropyrimidine polymer, with 5-ethynyl-2′-deoxyuridine (EdU) induces pronounced telomere attrition and mitotic catastrophe in colorectal cancer (CRC) cells. This mechanistic synergy highlights new strategies for targeting telomere maintenance and DNA damage in cancer therapy.

• Quizartinib (AC220): Transforming FLT3 Research in AML

  2026-06-27

  This thought-leadership article examines how Quizartinib (AC220), a potent and selective FLT3 inhibitor, is redefining translational research in acute myeloid leukemia (AML). By integrating advanced mechanistic insight, best-practice experimental approaches, and strategic guidance for resistance and in vivo modeling, we position Quizartinib as a cornerstone for next-generation FLT3-targeted research. The discussion uniquely bridges evidence from recent advances in cell death pathways and selective protein secretion, providing a nuanced vision for future research.

• Salinomycin: Mechanistic Leverage in Hepatocellular Carcinom

  2026-06-26

  This in-depth thought-leadership article explores the mechanistic, translational, and strategic dimensions of Salinomycin—a polyether ionophore antibiotic—within hepatocellular carcinoma (HCC) research. Integrating evidence from foundational molecular studies and recent advances, we chart a course for maximizing workflow rigor, experimental reproducibility, and future impact. The article critically engages with toxicity considerations, unique mechanistic hallmarks, and practical deployment strategies for translational researchers, while also contrasting Salinomycin’s utility against the broader landscape of ionophore and anti-cancer agents.

• PBS (Phosphate-Buffered Saline): Technical Use and Protocols

  2026-06-26

  PBS (Phosphate-Buffered Saline, SKU K2818) provides a sterile, isotonic buffer with physiological pH control, ideal for cell washing, dilution, and in vitro assays in laboratory research. It should not be used in diagnostic or clinical applications, and is optimized for workflows requiring pH and osmolarity stability.

• Pyridostatin TFA: Transforming G-Quadruplex Research Frontie

  2026-06-25

  This article explores how Pyridostatin TFA, a synthetic G-quadruplex DNA structure stabilizer, is reshaping translational research in telomere biology, cancer, and neurodegeneration. We blend mechanistic insight, protocol guidance, and evidence from recent studies—including the impact of G-quadruplexes on TDP-43 toxicity—offering a strategic roadmap for researchers at the intersection of cancer and protein misfolding diseases.

• Murine RNase Inhibitor: Precision RNA Protection for Advance

  2026-06-25

  Murine RNase Inhibitor from APExBIO offers oxidation-resistant RNA protection, crucial for high-sensitivity applications like real-time RT-PCR and cDNA synthesis. Its unique stability under low reducing conditions gives researchers new flexibility and reliability in preserving RNA integrity across complex experimental designs.

• CD40–STING–TRAF2 Axis Drives B Cell Activation in ESCC TLS

  2026-06-24

  This study elucidates how competitive binding between CD40 and STING with TRAF2 regulates IRF4-mediated B cell activation within tertiary lymphoid structures (TLS) in esophageal squamous cell carcinoma (ESCC). The findings reveal a mechanistic pathway underpinning TLS-driven antitumor immunity and offer new directions for biomarker discovery and therapeutic targeting.

• E. coli Uracil-DNA Glycosylase (UDG): Technical Lab Guidance

  2026-06-23

  E. coli Uracil-DNA Glycosylase (UDG) enables precise removal of uracil from DNA, addressing PCR contamination and supporting DNA repair research. It is not appropriate for RNA, very short oligonucleotides, or any diagnostic or medical workflows.

• Patient-Derived Gastric Cancer Assembloids Reveal Microenvir

  2026-06-23

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations, enabling more accurate recapitulation of tumor heterogeneity and microenvironmental influences. The model demonstrates that stromal components significantly impact gene expression and drug response, providing a superior platform for studying drug resistance mechanisms and optimizing personalized therapies.

455 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page